Holding(s) in Company

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: 

Verona Pharma plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: 

Abingworth LLP

Abingworth Bioventures VI LP

4. Full name of shareholder(s) (if different from 3.):

State Street (Nominees) Limited (as nominee for Abingworth Bioventures V LP)

5. Date of the transaction and date onwhich the threshold is crossed orreached: 

3 May 2017

6. Date on which issuer notified:

5 May 2017

7. Threshold(s) that is/are crossed orreached: 

Upward crossing of the 7%, threshold

8. Notified details: Abingworth LLP

A: Voting rights attached to shares 

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights 

Direct

Direct

Indirect 

Direct

Indirect

Verona Pharma plc

GB00B06GSH43

5p Ords

3,510,553

3,510,553

3,510,553

0

3,510,553

0

3.55%

Verona Pharma plc US9250501064

ADSs

3,705,000

0

3,705,000

0

3.74%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate 

Exercise/Conversion Period 

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments 

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date 

Exercise/Conversion period

Number of voting rights instrument refers to

% of voting rights 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

7,215,553

7.29%

8. Notified details: Abingworth Bioventures VI LP

A: Voting rights attached to shares 

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights 

Direct

Direct 

Indirect 

Direct

Indirect

Verona Pharma plc

GB00B06GSH43

5p Ords

3,510,553

3,510,553

3,510,553

3,510,553

0

3.55%

0

Verona Pharma plc US9250501064

ADSs

3,705,000

3,705,000

0

3.74

0

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate 

Exercise/Conversion Period 

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments 

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date 

Exercise/Conversion period 

Number of voting rights instrument refers to

% of voting rights 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

7,215,553

7.29%

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: 

Abingworth Bioventures VI LP (which holds 7,215,553 shares in the company (7.29%)) is managed by Abingworth LLP.

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

John Heard

15. Contact telephone number:

020 7534 1500